文献速递浆细胞疾病

伊沙妥昔单抗、硼替佐米、来那度胺及限用地塞米松治疗不适合移植的多发性骨髓瘤患者(REST):一项多中心、单臂、2期试验

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2025-01-01

REST是一项多中心单臂2期试验,评估伊沙妥昔单抗、每周硼替佐米、来那度胺及仅前两周期使用地塞米松方案治疗不适合自体造血干细胞移植的新诊断多发性骨髓瘤患者。共纳入51例患者,中位年龄77岁,中位随访27.0个月时,19例(37%[95%CI 25.3-51.0])达到MRD阴性完全缓解。最常见3-4级不良事件为中性粒细胞减少(28例[55%])、感染(21例[41%])和血小板减少(11例[22%])。

要点

  • 51例不适合移植的新诊断多发性骨髓瘤患者接受伊沙妥昔单抗、每周硼替佐米、来那度胺及仅前两周期地塞米松治疗。
  • 中位随访27.0个月,19例(37%[95%CI 25.3-51.0])达到MRD阴性完全缓解。
  • 3-4级不良事件以中性粒细胞减少(55%)、感染(41%)和血小板减少(22%)最常见。

核心结论

  • 伊沙妥昔单抗、每周硼替佐米和来那度胺联合限用地塞米松作为不适合自体HSCT的老年多发性骨髓瘤患者的初始治疗具有活性和安全性。
  • 作者认为,两周期后省略地塞米松的改良四联方案可用于该患者人群。

研究设计与样本

  • REST为学术性、多中心、单臂、2期试验,纳入新诊断多发性骨髓瘤且有不适合大剂量美法仑和自体HSCT、ECOG体能状态0-3(3分仅允许与骨髓瘤相关)的成人患者。
  • 患者接受28天周期治疗:伊沙妥昔单抗10 mg/kg静脉给药(第1周期第1、8、15、22天,第2-18周期第1、15天),硼替佐米1.3 mg/m2皮下给药(第1-8周期第1、8、15天),来那度胺25 mg口服(第1-21天,直至疾病进展),地塞米松20 mg口服(第1、8、15、22天,仅限前两周期)。
  • 主要终点为治疗18周期内或之后经下一代流式细胞术(灵敏度1.0×10^-5)评估的MRD阴性完全缓解。
  • 2021年6月30日至2023年1月19日共招募51例患者(27例[53%]女性,24例[47%]男性),中位年龄77岁(IQR 73.5-80)。
  • 所有入组患者均开始治疗并纳入分析;试验注册号ClinicalTrials.gov NCT04939844,随访正在进行。

主要发现

  • 中位随访27.0个月(IQR 23.0-33.7),19例(37%[95%CI 25.3-51.0])达到MRD阴性完全缓解,中位治疗持续时间22个月(IQR 15.2-28.8;范围1.4-35.1)。
  • 51例患者中18例(35%)发生疾病进展或死亡,8例(16%)死亡。
  • 前18周期治疗中,最常见的3-4级不良事件为中性粒细胞减少(28例[55%])、感染(21例[41%])和血小板减少(11例[22%])。
  • 27例(53%)患者报告48例次3级及以上严重不良事件;14例(27%)患者在19周期前终止治疗,最常见原因为疾病进展(8例[16%])和不良事件(4例[8%])。
  • 两例死亡(一例肺炎、一例脓毒症)被评估为可能与研究治疗相关。

关键数值与推荐

  • MRD阴性完全缓解定义为经下一代流式细胞术(灵敏度1.0×10^-5)评估达到MRD阴性的完全缓解。
  • 39例参与者按方案完成18周期治疗,其中2例已终止治疗但未终止方案。

临床怎么用

  • 作者认为,两周期后省略地塞米松的改良四联方案可用于不适合自体HSCT的老年多发性骨髓瘤患者人群。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adding anti-CD38 monoclonal antibodies to standard therapies can improve outcomes in patients with multiple myeloma. Long-term treatment with corticosteroids increases the risk of infection. We aimed to evaluate the safety and activity of isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone in patients with newly diagnosed multiple myeloma ineligible for autologous haematopoietic stem-cell transplantation (HSCT). METHODS: REST is an academic, multicentre, single-arm, phase 2 trial of adults with newly diagnosed multiple myeloma and measurable disease as defined by International Myeloma Working Group criteria, ineligible for high-dose melphalan and autologous HSCT, Eastern Cooperative Oncology Group performance status of 0-3 (with 3 only allowed if related to myeloma). In 28-day cycles, patients received isatuximab (10 mg/kg intravenously on days 1, 8, 15, and 22 of cycle 1, and days 1 and 15 of cycles 2-18), bortezomib (1·3 mg/m2 subcutaneously on days 1, 8, and 15 of cycles 1-8), and lenalidomide (25 mg orally on days 1-21, until progressive disease). Dexamethasone was given 20 mg orally on days 1, 8, 15 and 22, limited to the two first cycles only. The primary endpoint was measurable residual disease (MRD)-negative complete response, assessed by next-generation flow cytometry (sensitivity 1·0 × 10-5), during or after 18 cycles of study treatment. MRD was tested in all patients who had at least complete response before cycle 19 and in all patients who had at least very good partial response at cycle 19. All patients enrolled initiated treatment and were included in the analyses. This trial is registered with ClinicalTrials.gov (NCT04939844); the primary endpoint is reported in this Article, and follow-up is ongoing. FINDINGS: Between June 30, 2021 and Jan 19, 2023, we assessed for eligibility and recruited 51 patients (27 [53%] females and 24 [47%] males), with a median age of 77 years (IQR 73·5-80). 39 participants completed 18 cycles of treatment on protocol, of whom two had discontinued treatment but not protocol. At a median follow-up of 27·0 months (IQR 23·0-33·7), MRD-negative complete response was observed in 19 (37% [95% CI 25·3-51·0]) patients, with a median treatment duration of 22 months (IQR 15·2-28·8; range 1·4-35·1). Disease progression or death had occurred in 18 (35%) of 51 patients, and eight (16%) patients had died. During the first 18 cycles of study treatment, the most common adverse events of grade 3 or 4 were neutropenia (28 [55%] patients), infections (21 [41%] patients), and thrombocytopenia (11 [22%] patients). 48 serious adverse events of grade 3 or higher were reported in 27 (53%) patients. A total of 14 (27%) patients discontinued treatment before cycle 19, most commonly because of progressive disease (eight [16%]) and adverse events (four [8%]). Two deaths (one due to pneumonia and one due to sepsis) were assessed as possibly related to study treatment. INTERPRETATION: Isatuximab, weekly bortezomib, and lenalidomide with limited dexamethasone was active and safe as initial therapy for older patients with multiple myeloma ineligible for autologous HSCT. A modified quadruplet regimen in which dexamethasone is omitted after two cycles can be used in this patient population. FUNDING: Sanofi.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Askeland FB, Haukås E, Slørdahl TS, et al. Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2025. PMID: 39909655. doi:10.1016/S2352-3026(24)00347-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。